製品番号: HY-190897

11F-CPT

11F-CPT is a Topoisomerase I inhibitor that stabilizes the TOP I-DNA cleavage complex. 11F-CPT inhibits TOP I-mediated DNA relaxation, induces DNA damage, and activates ATR-CHK1 signaling. 11F-CPT selectively inhibits proliferation and colony formation in pancreatic cancer cells, upregulates γ‑H2AX, and induces cell cycle arrest and apoptosis. 11F-CPT inhibits tumor growth in the PAN02 pancreatic cancer xenograft model and enhances the thermal stability of TOP I in cells. 11F-CPT can be used for research on pancreatic cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 186036-91-9
分子式: C₂₀H₁₅FN₂O₄
分子量:366.34

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

11F-CPT 構造式

CAS 番号: 186036-91-9

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

^[1]

Topoisomerase I

Caspase 3

Bax

bad

Bcl-2

Topoisomerase アイソフォーム固有の製品をすべて表示 :

Caspase アイソフォーム固有の製品をすべて表示 :

Bcl-2 Family アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC50	0.110 μM	Antiproliferative activity against human HepG2 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human HepG2 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
A549	IC50	0.262 μM	Antiproliferative activity against human A549 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human A549 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
MCF7	IC50	0.205 μM	Antiproliferative activity against human MCF-7 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human MCF-7 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
SW480	IC50	0.101 μM	Antiproliferative activity against human SW480 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human SW480 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
T-24	IC50	0.006 μM	Antiproliferative activity against human T24 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human T24 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
UMUC3	IC50	0.002 μM	Antiproliferative activity against human UMUC3 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human UMUC3 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
PANC-1	IC50	0.164 μM	Antiproliferative activity against human PANC-1 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human PANC-1 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
BXPC-3	IC50	0.002 μM	Antiproliferative activity against human BxPC-3 cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human BxPC-3 cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683
L02	IC50	0.0193 μM	Cytotoxicity against normal human L02 liver cells assessed as viability reduction incubated 48 hrs by MTT assay. Cytotoxicity against normal human L02 liver cells assessed as viability reduction incubated 48 hrs by MTT assay.	42911683

体外実験

Anti-cancerApoptosisCell Cycle RegulationOthers

Anti-cancer

11F-CPT (compound W3) (48 h) is highly cytotoxic in these cancer cell lines, with the lowest IC₅₀ values in UMUC3 and BxPC-3 cells (0.002 μM) and potent activity in A549 cells (0.262 μM)^[1].
11F-CPT (0.01-0.25 μM for BxPC-3; 0.1-2.5 μM for PANC-1; 24 h-14 days) reduces EdU incorporation and decreases colony formation in BxPC-3 and PANC-1 pancreatic cancer cells^[1].
11F-CPT (0.01 μM for BxPC-3; 0.1 μM for PANC-1; 48 h) increases the proportion of γ-H2AX-positive BxPC-3 and PANC-1 pancreatic cells^[1].
11F-CPT (0.5 μM for BxPC-3; 2.5 μM for PANC-1) inhibits the catalytic activity of TOP I in BxPC-3 and PANC-1 pancreatic cancer cells^[1].
11F-CPT enhances the thermal stability of TOP I in BxPC-3 pancreatic cancer cells and increases the DNA-bound TOP I^[1].
11F-CPT (0.1 μM) increases γ-H2AX and activates p-ATR/p-CHK1 signaling in BxPC-3 pancreatic cancer cells^[1].

Anti-cancer

Apoptosis

11F-CPT (0.01-0.25 μM for BxPC-3; 0.1-2.5 μM for PANC-1; 48 h) induces apoptosis in BxPC-3 and PANC-1 pancreatic cancer cells, increases Bax, Bad, and cleaved caspase-3, and decreases Bcl-2 and increases γ-H2AX protein levels^[1].

Anti-cancer

Cell Cycle Regulation

11F-CPT (0.01-0.25 μM for BxPC-3; 0.1-2.5 μM for PANC-1; 24 h) induces S phase accumulation in BxPC-3 and PANC-1 pancreatic cancer cells and causes G2/M phase arrest at higher concentrations; it also upregulates p53/p21 and CCNA1/CCNB1 and downregulates CCND1/CCNE1^[1].

Others

11F-CPT (0.25-1.5 μM; 30 min) inhibits TOP I-mediated DNA relaxation in a cell-free system^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

BxPC-3 and PANC-1 human pancreatic cancer cells
Concentration:

0.01, 0.05, and 0.25 μM (BxPC-3)
0.1, 0.5, and 2.5 μM (PANC-1)
Incubation Time:

24 h
Result:

Reduced EdU incorporation in BxPC-3 and PANC-1 pancreatic cancer cells.

Cell Proliferation Assay^[1]

Cell Line:

BxPC-3 and PANC-1 human pancreatic cancer cells
Concentration:

0.01, 0.05, and 0.25 μM (BxPC-3)
0.1, 0.5, and 2.5 μM (PANC-1)
Incubation Time:

14 days
Result:

Markedly reduced colony numbers in BxPC-3 cells.
Suppressed colony formation in PANC-1 cells.

Cell Cycle Analysis^[1]

Cell Line:

BxPC-3 and PANC-1 human pancreatic cancer cells
Concentration:

0.01, 0.05, and 0.25 μM (BxPC-3)
0.1, 0.5, and 2.5 μM (PANC-1)
Incubation Time:

24 h
Result:

Induced S-phase accumulation and G2/M arrest at higher concentrations in BxPC-3 and PANC-1 pancreatic cancer cells.

Western Blot Analysis^[1]

Cell Line:

BxPC-3 and PANC-1 human pancreatic cancer cells
Concentration:

0.01, 0.05, and 0.25 μM (BxPC-3)
0.1, 0.5, and 2.5 μM (PANC-1)
Incubation Time:

24 h
Result:

Upregulated p53/p21 and CCNA1/CCNB1, while downregulating CCND1/CCNE1.

Apoptosis Analysis^[1]

Cell Line:

BxPC-3 and PANC-1 human pancreatic cancer cells
Concentration:

0.01, 0.05, and 0.25 μM (BxPC-3)
0.1, 0.5, and 2.5 μM (PANC-1)
Incubation Time:

48 h
Result:

Induced apoptosis in BxPC-3 and PANC-1 pancreatic cancer cells, reaching total apoptosis rates of 56.2% and 41.6%, respectively.

Western Blot Analysis^[1]

Cell Line:

BxPC-3 and PANC-1 human pancreatic cancer cells
Concentration:

0.01, 0.05, and 0.25 μM (BxPC-3)
0.1, 0.5, and 2.5 μM (PANC-1)
Incubation Time:

48 h
Result:

Increased the levels of Bax, Bad, and cleaved caspase-3, and decreases the level of Bcl-2.
Increased γ-H2AX protein levels in BxPC-3 and PANC-1 pancreatic cancer cells.

Immunofluorescence^[1]

Cell Line:

BxPC-3 and PANC-1 human pancreatic cancer cells
Concentration:

0.01 μM (BxPC-3)
0.1 μM (PANC-1)
Incubation Time:

48 h
Result:

Increased the proportion of γ-H2AX-positive BxPC-3 cells at 0.01 μM and markedly increased γ-H2AX-positive PANC-1 cells at 0.1 μM.

体内実験

Anti-cancer

11F-CPT (compound W3) (0.3-1.0 mg/kg; i.p.; once every other day; seven doses within 14 days) inhibits the growth of PAN02 subcutaneous tumors in C57BL/6J mice, achieving a tumor inhibition rate of 60.2% at 1.0 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6J (female, 2 × 10⁶ PAN02 cells in 150 μL)^[1]
Dosage:

0.3, 1.0 mg/kg
Administration:

i.p.; every other day; seven doses over 14 days
Result:

Inhibited tumor growth substantially at all tested doses, as assessed by tumor volume and tumor weight.
Reached tumor inhibition rates of 42.4% at 0.3 mg/kg and 60.2% at 1.0 mg/kg at the Day 14 endpoint.

Related Protocols :

化学情報

CAS 番号 186036-91-9
分子量 366.34
分子式 C₂₀H₁₅FN₂O₄
SMILES

O=C1C2=C([C@](CC)(O)C(OC2)=O)C=C3C4=NC5=CC(F)=CC=C5C=C4CN31
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Chen GS, et al. Design, Synthesis, and Biological Evaluation of Novel, Fluorinated Camptothecin Derivatives as Potential Topoisomerase I Inhibitors. Journal of medicinal chemistry. 2026 Oct 22;69(20):24030-24052. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

11F-CPT

Topoisomerase アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

Bcl-2 Family アイソフォーム固有の製品をすべて表示

生物活性

製品説明

IC₅₀ & Target

Cellular Effect

体外実験

体内実験

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Bioz

Keywords

最近チェックした製品

11F-CPT

Topoisomerase アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

Bcl-2 Family アイソフォーム固有の製品をすべて表示

生物活性

製品説明

IC50 & Target

Cellular Effect

体外実験

体内実験

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

11F-CPT 関連分類

HY-190897 関連分類

Bioz

Keywords

最近チェックした製品

IC₅₀ & Target